The company, founded earlier this year, is developing a technology for the detection of low-frequency genetic mutations for diagnostic applications.
The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.